David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Targa Resources
TRGP
$62.2B
| $2.44M | ﹤0.01% |
58,786
+33,223
| +130% | +$1.39M |
|
|
LHCG
1977
CALL
DELISTED
LHC Group LLC
LHCG
| $2.44M | ﹤0.01% |
22,000
+8,700
| +65% | +$928K |
|
1978
Foster
FSTR
$395M
| $2.44M | ﹤0.01% |
129,401
-3,134
| -2% | -$55.7K |
|
1979
CALL
Ionis Pharmaceuticals
IONS
$10.5B
| $2.44M | ﹤0.01% |
+30,000
| New | +$1.94M |
|
1980
NVR
NVR
$16.8B
| $2.44M | ﹤0.01% |
880
+50
| +6% | +$132K |
|
|
USCR
1981
PUT
DELISTED
U S Concrete, Inc.
USCR
| $2.44M | ﹤0.01% |
58,800
-112,000
| -66% | -$4.3M |
|
1982
Lennar Class B
LEN.B
$20.3B
| $2.43M | ﹤0.01% |
65,399
-10,189
| -13% | -$364K |
|
1983
Caesarstone
CSTE
$116M
| $2.42M | ﹤0.01% |
155,147
+74,294
| +92% | +$1.16M |
|
|
ACOR
1984
DELISTED
Acorda Therapeutics
ACOR
| $2.42M | ﹤0.01% |
1,516
-565
| -27% | -$1.02M |
|
|
K
1985
CALL
DELISTED
Kellanova
K
| $2.4M | ﹤0.01% |
44,624
+28,649
| +179% | +$1.53M |
|
1986
PUT
Paycom
PAYC
$10.7B
| $2.4M | ﹤0.01% |
12,700
+9,600
| +310% | +$1.56M |
|
1987
Schneider National
SNDR
$6.18B
| $2.4M | ﹤0.01% |
114,039
+51,924
| +84% | +$1.11M |
|
1988
CALL
McKesson
MCK
$104B
| $2.4M | ﹤0.01% |
20,500
-21,900
| -52% | -$2.7M |
|
1989
PUT
Tandem Diabetes Care
TNDM
$1.48B
| $2.4M | ﹤0.01% |
37,800
-284,800
| -88% | -$15M |
|
1990
Hanmi Financial
HAFC
$916M
| $2.39M | ﹤0.01% |
112,327
-11,206
| -9% | -$244K |
|
1991
Gentex
GNTX
$4.93B
| $2.38M | ﹤0.01% |
114,949
-44,010
| -28% | -$920K |
|
1992
Prestige Consumer Healthcare
PBH
$2.44B
| $2.37M | ﹤0.01% |
79,348
-30,948
| -28% | -$887K |
|
1993
CALL
Diageo
DEO
$51.3B
| $2.37M | ﹤0.01% |
+14,500
| New | +$2.21M |
|
|
ACR
1994
ACRES Commercial Realty
ACR
$103M
| $2.37M | ﹤0.01% |
74,278
-800
| -1% | -$25.4K |
|
1995
PUT
Interactive Brokers
IBKR
$44.1B
| $2.36M | ﹤0.01% |
181,600
+14,800
| +9% | +$195K |
|
1996
PUT
Toyota
TM
$228B
| $2.36M | ﹤0.01% |
20,000
| – | – |
|
1997
SandRidge Energy
SD
$513M
| $2.35M | ﹤0.01% |
293,649
+182,392
| +164% | +$1.49M |
|
|
SEMG
1998
DELISTED
SEMGROUP CORPORATION
SEMG
| $2.35M | ﹤0.01% |
+159,523
| New | +$2.52M |
|
1999
Thor Industries
THO
$4.02B
| $2.35M | ﹤0.01% |
37,675
-15,140
| -29% | -$959K |
|
2000
Biglari Holdings Class B
BH
$1.22B
| $2.35M | ﹤0.01% |
16,617
-400
| -2% | -$52.6K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $2.66B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.